Jorge Plutzky

Jorge Plutzky

Auto-generated profile, based on publicly available information

Jorge Plutzky

Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Molecular Cell
Verified
Journal Article
Closed access
JBJonathan D. Brown
Jonathan D. Brown
CLCharles Y. Lin
Charles Y. Lin
QDQiong Duan
Qiong Duan
GGGabriel Griffin
Gabriel Griffin
AFAlexander J. Federation
Alexander J. Federation
JPJorge Plutzky
Jorge Plutzky

22 June 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
NMNikolaus Marx
Nikolaus Marx
GSGalina K. Sukhova
Galina K. Sukhova
TCTucker Collins
Tucker Collins
PLPeter Libby
Peter Libby
JPJorge Plutzky
Jorge Plutzky
Background—Adhesion molecule expression on the endothelial cell (EC) surface is critical for leukocyte recruitment to atherosclerotic lesions. Better understanding of transcriptional regulation of adhesion molecules in ECs may provide important insight into plaque formation. Peroxisome proliferator–activated receptor-α (PPARα), a member of the nuclear receptor family, regulates gene expression in response to certain fatty acids and fibric acid derivatives. The present study investigated PPARα expression in human ECs and their regulation of vascular cell adhesion molecule-1 (VCAM-1).Methods and Results—Immunohistochemistry revealed that human carotid artery ECs express PPARα. Pretreatment of cultured human ECs with the PPARα activators fenofibrate or WY14643 inhibited TNF-α–induced VCAM-1 in a time- and concentration-dependent manner, an effect not seen with PPARγ activators. Both PPARα activators decreased cytokine-induced VCAM-1 mRNA expression without altering its mRNA half-life. Transient transfection of deletional VCAM-1 promoter constructs and electrophoretic mobility shift assays suggest that fenofibrate inhibits VCAM-1 transcription in part by inhibiting NF-κB. Finally, PPARα activators significantly reduced adhesion of U937 cells to cultured human ECs.Conclusions—Human ECs express PPARα, a potentially important regulator of atherogenesis through its transcriptional control of VCAM-1 gene expression. Such findings also have implications regarding the clinical use of lipid-lowering agents, like fibric acids, which can activate PPARα.

1 February 2009 in JACC
Verified
Journal Article
Closed access
GOGabriela Orasanu
Gabriela Orasanu
JPJorge Plutzky
Jorge Plutzky

13 May 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DRDonna H Ryan
Donna H Ryan
ILIldiko Lingvay
Ildiko Lingvay
JDJohn Deanfield
John Deanfield
SKSteven E. Kahn
Steven E. Kahn
Eric BarrosEric Barros
Eric Barros
RKRobert F. Kushner
Robert F. Kushner
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m−2) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier: NCT03574597.

27 May 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Ouliana ZiouzenkovaOuliana Ziouzenkova
Ouliana Ziouzenkova
GOGabriela Orasanu
Gabriela Orasanu
MSMolly Sharlach
Molly Sharlach
TATaro E Akiyama
Taro E Akiyama
JBJoel P Berger
Joel P Berger
JPJorge Plutzky
Jorge Plutzky

30 January 2007 in Circulation
Verified
Journal Article
Open access
PDF file
JBJonathan D. Brown
Jonathan D. Brown
JPJorge Plutzky
Jorge Plutzky
Peroxisome proliferator–activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity. More recent work implicates all 3 PPAR isotypes (α, γ, and δ, also known as β or β/δ) in inflammatory and atherosclerotic pathways. Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated. The ongoing clinical use of fibrates, which activate PPARα, and thiazolidinediones, which activate PPARγ, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators. Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.